Ovarian Cancer Treatment Drugs Market Trends, Size, Competitive Analysis and Forecast 2021-2027
The global ovarian cancer treatment drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The rising prevalence of ovarian cancer is the major factor accelerating market growth. Ovarian cancer is the second most common gynecologic cancer in the US. The American Cancer Society (ACS) estimates that there will be nearly 19,880 women receiving a new diagnosis of ovarian cancer in the US. Growing consumption of contraceptives and declining use of hormonal therapies are resulting in a reduced mortality rate due to ovarian cancer. The major factor that is expected to accelerate the growth of the market during the forecast period includes the increasing incidence of ovarian cancer. The need for more effective treatment options is another factor that is fuelling the growth of the market. While the market is dominated by generics such as paclitaxel and carboplatin, it is expected that drugs such as Bevacizumab (Avastin), Pazopanib (Votrient) would boost the growth of this market. The development of drugs with improved efficacy is a challenge for this market. The opportunity for this market lies in developing new drugs for treating ovarian cancer.
To Request a Sample of our Report on Ovarian Cancer
Treatment Drugs Market: https://www.omrglobal.com/request-sample/ovarian-cancer-treatment-drugs-market
The current research in ovarian cancer is focused on
using novel treatments such as immunotherapy, targeted therapy, and most
importantly combination regimens. Immuno-oncologic agents have shown promising
results with improved survival and lower toxicity. However, a single-agent
response rate of PD-1/ PD-L1 molecules such as Opdivo and Keytruda for ovarian
cancer treatment is less than 20.0%. Combination therapies, specifically those
including checkpoint inhibitors, are poised to be introduced in the first-line
setting to target major unmet needs including overcoming tumor resistance, improving
progression-free survival, and maintaining the quality of life.
Market Coverage
• The
market number available for – 2020-2027
• Base
year- 2020
• Forecast
period- 2021-2027
• Segment
Covered-
·
By Type
·
By Application
• Regions
covered-
·
North America
·
Europe
·
Asia-Pacific
·
Rest of the World
·
Competitive Landscape: F. Hoffman
La-Roche AG, GlaxoSmithKline plc, and AstraZeneca plc, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Ovarian Cancer Treatment Drugs Marke tis Available
at: https://www.omrglobal.com/industry-reports/ovarian-cancer-treatment-drugs-market
Global Ovarian Cancer Treatment Drugs Market Report by
Segment
By Type
• Platinum
Anti-Cancer Drugs
• Fluoropyrimidine
• Anthracycline
Antibiotics
• Therapeutic
Antibody
• Small
Molecules Drug
• Aromatase
Inhibitors
• Anti-Estrogens
By Application
• Hospitals
• Clinics
• Drug
Store
• Others
Global Ovarian Cancer Treatment Drugs Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
·
Latin America
·
Middle East & Africa
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment